HLA-Independent Killing Assay Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs provides an HLA-Independent Killing Assay Service to address key challenges in cell therapy development, including viral immune evasion, tumor antigen escape, and the limitations of MHC-restricted target recognition. This service enables the functional validation of non-canonical immune effectors such as CAR-T, TRuC-T, and γδ T cells through advanced co-culture platforms and high-sensitivity cytotoxicity monitoring. By bypassing HLA-restriction barriers, Creative Biolabs supports accurate potency evaluation, accelerates lead optimization, and ensures robust anti-tumor efficacy against difficult or immune-evasive targets.

Introduction

HLA-independent cytotoxicity refers to immune-mediated tumor cell killing that does not require antigen presentation via HLA class I molecules. This mechanism is characteristic of natural killer cells and several engineered immune cell platforms. Studies have shown that cytotoxic lymphocytes can eliminate tumor targets lacking classical antigen presentation pathways or exhibiting altered HLA expression profiles. HLA-independent killing assays, therefore provide an essential functional approach for evaluating immune cell therapies, identifying cytotoxic mechanisms, and validating immune effector potency in cancer research.

Service

Creative Biolabs provides a specialized testing framework designed to evaluate the cytotoxic potential of HLA-independent agents, such as CAR-T cells, TRuCs (T cell receptor fusion constructs), and bispecific antibodies. Our service is engineered to prove that your therapy can eliminate target cells even when the Human Leukocyte Antigen (HLA) system is compromised or bypassed. By utilizing high-sensitivity assays, we provide the definitive proof-of-concept data required for regulatory filings and downstream development.

Our Key Capabilities: Characterize immune effector functions by evaluating NK, engineered immune cell, and primary lymphocyte cytotoxicity against HLA-diverse tumor targets; engineer and validate HLA class I-altered tumor cell models for comparative cytotoxicity analysis; assess antigen-independent cytotoxic mechanisms via complementary assays; profile quantitative cytotoxicity, including killing efficiency, effector-to-target curves, and time-dependent activity with high-resolution platforms.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Creative Biolabs provides integrated experimental platforms designed to evaluate HLA-independent cytotoxicity under controlled conditions.

Precision Target Cell Engineering	Multi-Platform Cytotoxicity Quantification
HLA-Deficient Models: Created via similar tools to study immune evasion. HLA-Overexpressing Models: Used to test inhibitory signals or enhance visibility to T-cells. Isogenic Controls: Genetically identical lines (minus the HLA modification) that ensure observed effects are due to the target gene.	Endpoint Analysis: Flow Cytometry and Enzyme Release provide a precise "count" of dead vs. living cells at a specific time. Kinetic Monitoring: Real-time imaging and bioluminescence allow researchers to see how fast and in what manner the killing occurs over several days.
Effector Cell Characterization	Mechanistic & Secretory Profiling
Functional Potency: Establishing Effector-to-Target ratios to determine how many immune cells are needed to kill a certain percentage of tumor cells. Phenotypic Activation: Tracking markers to see if the immune cells are "awake" and ready to fight.	Cytokine Profiling: Measuring secreted proteins to understand the inflammatory environment. Dynamic Interactions: Analyzing the physical contact and "synapse" formation between the effector and the tumor cell.

Our Workflow

Required Starting Materials: To initiate the service, clients typically provide the Effector Cells, Target Cell Lines, and Specific Antibodies/Ligands if a bispecific or antibody-dependent cellular cytotoxicity (ADCC) mechanism is being tested.

Workflow of HLA-Independent Killing Assay. (Creative Biolabs Original)

Core Benefits

Comprehensive One-Stop Potency Assessment: From target cell line engineering (including MHC-knockout) to high-throughput cytotoxicity screening and final mechanism-of-action reporting.
Fully Customized Experimental Design: Tailored Effector-to-Target ratios, co-culture durations, and the inclusion of specific cytokines or immune checkpoint inhibitors to mimic your specific therapeutic context.
Diverse Effector & Target Library: Access to a vast array of validated MHC-deficient cell lines and the ability to work with various effector types, including NK, γδ T, and NK T cells.
Advanced Multiplex Analysis: Simultaneous quantification of degranulation markers and pro-inflammatory cytokine release to provide a holistic view of immune activation.

FAQs

Q1: How do you ensure the killing observed is truly HLA-independent?

A1: We utilize target cell lines that have been genetically modified to be HLA-null. This ensures that any observed lysis is mediated through non-MHC-restricted pathways. For more details on our cell line library, please inquire.

Q2: Can this assay be used for bispecific antibodies?

A2: Absolutely. Our platform is ideal for testing bispecific T-cell engagers or NK-cell engagers that link effectors to tumor antigens independently of the TCR-MHC interaction.

Q3: What is the advantage of real-time monitoring over endpoint assays?

A3: Real-time monitoring allows us to see when the killing starts and the rate at which it occurs. This is vital for distinguishing between rapid cytolysis and slower, apoptosis mediated pathways.

Q4: Are there any precautions regarding effector cell exhaustion?

A4: Yes, in long-term co-culture assays, effector exhaustion can occur. We offer phenotypic markers as an add-on service to monitor the fitness of your cells during the assay.

Partner with Us

Creative Biolabs provides comprehensive HLA-Independent Killing Assay Service solutions designed to support immune therapy research, immune cell functional validation, and tumor cytotoxicity studies. Through controlled target cell models, quantitative cytotoxicity platforms, and expert data interpretation, our services help researchers gain reliable insights into immune effector mechanisms. For detailed information or to discuss your specific project requirements, please contact us and our team of professional scientists will be ready to assist you.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.